Maxime Ronot

Diagnostic and interventional abdominal radiologist

[Maxime Ronot @maximeronot]

@BavenoCoop The trial is negative though

[Jean-Charles Nault @NaultJc]

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy | Targeted and Immune Therapy | JAMA Oncology | JAMA Network https://t.co/wtpCwy9cnI

[Maxime Ronot @maximeronot]

🚨EASL CPG on the management of HCC in @JHepatology
Major update!

✅ LI-RADS endorsed
✅ Refined treatment algo
✅ More evidence supporting locoregional treatments
✅ Up-to-date discussions

👉https://t.co/Co4RkGuC1k

[Journal of Hepatology @JHepatology]

🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️

✅Updated advice for managing patients with #HCC & comprehensive review of pertinent data

Full text👉https://t.co/IAMvBDv0CT

#CPGs
#LiverTwitter
@EASLnews
@EASLedu
@AleksanderKrag

[Arndt Vogel @ArndtVogel]

🔥off the press: Tumor burden with AFP improves survival prediction for TACE treated patients with HCC
@JHEP_Reports
https://t.co/hNo05PURIz
🔎 International observational study
👉Easy to use tool to predict outcome
@myESMO @EASLedu @ILCAnews

[JHEP Reports @JHEP_Reports]

❕Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study

🔓#OpenAccess at👉https://t.co/eu79q98Ckz

#LiverTwitter
#HCC
@NaultJc

[Jean-Charles Nault @NaultJc]

Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology https://t.co/xtfuU9hJS5

[Maxime Ronot @maximeronot]

@JonathanStineMD @AASLDtweets Who takes the photos?

[@RadiologyEditor @RadiologyEditor]

🩺MRI-assessed intratumoral fat was generally nonprognostic; however, homogeneous intratumoral fat correlated with longer recurrence-free and overall survival in an Asian cohort of hepatocellular carcinoma patients. Findings from @maximeronot!
https://t.co/4tIWIsWaP4

[Arndt Vogel @ArndtVogel]

Risk of HCC in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound
@AGA_CGH
https://t.co/05xviGMIjC
🔎 Systematic Review, 9 studies, 888 pts
👉risk of HCC: 21.3%
👉risk factors: older age, male sex, elevated AFP, low plts, CP B
🧐repeat ultrasound in 3-6 mo reasonable
@myESMO @EASLnews @ILCAnews #livertwitter

[roypounder.apt @APandT]

Read 'open access' at https://t.co/JqSze6d9kQ
"Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts" by Mårild et al
#GItwitter #IBD

[Journal of Hepatology @JHepatology]

💥EXPERT OPINION

Integration of new technologies in the multidisciplinary approach to primary liver tumours

➡️The next-generation tumour board

Full text here👉https://t.co/3fyR1KrxpE

@Naultjc
#LiverTwitter

[Arndt Vogel @ArndtVogel]

🔥off the press
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC
@JHEP_Reports
🔎🗺️RWD study
❓how to best select for TACE > AFP & Tumor burden
🧐helpful for the discussion in the tumor board
👇my author link:
https://t.co/c6ECELXhvQ
@myESMO @EASLedu @ILCAnews #livertwitter

[Jean-Charles Nault @NaultJc]

The position paper from EASL about "management of rare primary liver cancers" was recently published in Journal Of Hepatology @EASLnews @JHepatology @campani_claudia @Zucmanrossi @ma5RN https://t.co/jL8p7YsXBc

[Arndt Vogel @ArndtVogel]

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC
#ESMO24
🔎IMbrave050
👉RFS 33.2 vs 36 mo, HR 0.9
👉OS: HR: 1.26
🧐Benefit not sustained! Disappointing..
🧐Caveat of (too) early read outs…
@myESMO #ESMOAmbassadors @ILCA @EASLedu

[Arndt Vogel @ArndtVogel]

Preoperative mFOLFIRINOX with or without CRT in borderline resectable #PDAC
#ESMO24
🔎Phs II trial PANDAS/PRODIGE 44
👉R0 resection 50 vs 55%
👉mOS 32.8 vs 30 mo
👉mOS 35.7 vs 47.9 mo (resected)
🧐no benefit in R0 rate or OS for CRT
🧐 mFOLFIRINOX with favorable OS

[Roberto Cannella @cannella_rob]

Congratulations to @F_matteini and team @marco_dioguardi @maximeronot @DrF_Vernuccio for the article "Discontinuous peripheral enhancement of focal liver lesions on CT and MRI: outside the box of typical cavernous hemangioma" published in @Abdominal_Rad

🔗https://t.co/DlcoXSa78k

[Radiology @radiology_rsna]

🚨 A new episode of the @radiology_rsna podcast is now available! 🚨 @LindaChuMD speaks with Dr. Lorenzo Garzelli and @maximeronot about Predictors of Intestinal Resection–Free Survival after Endovascular Revascularization #RadPodcasts https://t.co/VjESyhJfum

[Maxime Ronot @maximeronot]

@JHepatology And probably one of the best names for a protein

[Maxime Ronot @maximeronot]

Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies

Amazing collective work 💪
Everything there is to know, and more!
+ a new set of imaging criteria to play with ⬇️
https://t.co/2RRbOgU0k8 @ValdigGroup
@RautouE